002826.SZ
易明医药
SZSE · Healthcare · C 制造业 · CN
CNY 17.07
−1.56%Year over year
Reported trailing growth
- Revenue
- +4.7%
- EBITDA
- —
- EBIT
- +107.7%
- EPS
- +158.2%
- Free cash flow
- +103.0%
- Operating cash flow
- +94.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.4%
- EBITDA
- +14.3%
- EBIT
- +21.8%
- Net income
- +28.0%
- EPS
- +29.5%
- Free cash flow
- +20.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026